APA (7th ed.) Citation

Wehler, T. C., Thomas, M., & Schumann, C. (2017). A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer. Lung cancer, 108, . https://doi.org/10.1016/j.lungcan.2017.03.001

Chicago Style (17th ed.) Citation

Wehler, Thomas Christian, Michael Thomas, and Christian Schumann. "A Randomized, Phase 2 Evaluation of the CHK1 Inhibitor, LY2603618, Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Nonsquamous Non‐small Cell Lung Cancer." Lung Cancer 108 (2017). https://doi.org/10.1016/j.lungcan.2017.03.001.

MLA (9th ed.) Citation

Wehler, Thomas Christian, et al. "A Randomized, Phase 2 Evaluation of the CHK1 Inhibitor, LY2603618, Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Nonsquamous Non‐small Cell Lung Cancer." Lung Cancer, vol. 108, 2017, https://doi.org/10.1016/j.lungcan.2017.03.001.